Albireo Pharma Inc (NASDAQ:ALBO) – Equities research analysts at Jefferies Financial Group lifted their FY2019 EPS estimates for shares of Albireo Pharma in a research report issued to clients and investors on Wednesday, November 6th. Jefferies Financial Group analyst E. Yang now forecasts that the biopharmaceutical company will post earnings per share of ($6.14) for the year, up from their prior estimate of ($6.34). Jefferies Financial Group also issued estimates for Albireo Pharma’s Q4 2019 earnings at ($1.66) EPS, Q3 2020 earnings at ($0.94) EPS, FY2020 earnings at ($4.71) EPS, FY2021 earnings at ($5.75) EPS, FY2022 earnings at ($2.92) EPS and FY2023 earnings at $1.05 EPS.

Albireo Pharma (NASDAQ:ALBO) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.55) by ($0.18). The firm had revenue of $1.39 million during the quarter, compared to analyst estimates of $1.38 million. Albireo Pharma had a negative net margin of 2,403.88% and a negative return on equity of 51.74%.

ALBO has been the topic of several other research reports. HC Wainwright reissued a “buy” rating and issued a $62.00 target price on shares of Albireo Pharma in a report on Sunday, August 11th. William Blair reissued a “buy” rating on shares of Albireo Pharma in a report on Monday, July 15th. Wedbush reissued a “buy” rating and issued a $69.00 target price on shares of Albireo Pharma in a report on Wednesday, November 6th. Cowen reaffirmed a “buy” rating and set a $39.00 price objective on shares of Albireo Pharma in a research note on Wednesday, November 6th. Finally, BidaskClub lowered Albireo Pharma from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $49.00.

Albireo Pharma stock opened at $18.42 on Monday. The firm has a market capitalization of $257.26 million, a price-to-earnings ratio of -4.68 and a beta of 1.47. Albireo Pharma has a fifty-two week low of $16.13 and a fifty-two week high of $38.69. The stock’s fifty day moving average is $19.04 and its two-hundred day moving average is $26.92.

Several institutional investors and hedge funds have recently bought and sold shares of ALBO. Man Group plc boosted its stake in shares of Albireo Pharma by 770.4% during the second quarter. Man Group plc now owns 189,500 shares of the biopharmaceutical company’s stock valued at $6,109,000 after acquiring an additional 167,729 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Albireo Pharma by 14.7% during the second quarter. BlackRock Inc. now owns 658,767 shares of the biopharmaceutical company’s stock valued at $21,239,000 after acquiring an additional 84,575 shares during the last quarter. Chicago Capital LLC boosted its stake in shares of Albireo Pharma by 10.0% during the third quarter. Chicago Capital LLC now owns 222,549 shares of the biopharmaceutical company’s stock valued at $4,451,000 after acquiring an additional 20,308 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Albireo Pharma by 10.1% during the second quarter. Vanguard Group Inc. now owns 177,647 shares of the biopharmaceutical company’s stock valued at $5,727,000 after acquiring an additional 16,236 shares during the last quarter. Finally, Marshall Wace North America L.P. boosted its stake in shares of Albireo Pharma by 57.4% during the second quarter. Marshall Wace North America L.P. now owns 39,888 shares of the biopharmaceutical company’s stock valued at $1,286,000 after acquiring an additional 14,544 shares during the last quarter. 73.21% of the stock is currently owned by institutional investors and hedge funds.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Article: What are Bollinger Bands?

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.